Inclusion Criteria:  locally advanced, operable melanoma treated by immunotherapy or anti-BRAF and anti-MEK targeted therapies (stage IIIb, IIIc) or exclusive immunotherapy (stage IV) in an adjuvant situation.  Exclusion Criteria:  second cancer woman who is pregnant, likely to be pregnant or breastfeeding